# Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

> **NCT05635734** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cantex Pharmaceuticals** · enrollment: 18 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Azeliragon 5 mg
- **DRUG:** Azeliragon 10 mg
- **DRUG:** Azeliragon 20 mg

## Key facts

- **NCT ID:** NCT05635734
- **Lead sponsor:** Cantex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05635734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05635734, "Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT05635734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*